OxyContin's 1996 launch by Purdue Pharma took place as American medicine was redefining pain as a condition requiring more systematic assessment and treatment. Purdue presented the drug as a safe, dependable option for chronic pain, while its sales campaign connected that claim to changing hospital standards and professional pressure to relieve pain. The resulting story is not simply one of a new medicine entering the market: it is also one of commercial promotion finding a receptive clinical environment, followed by a crisis whose burdens and responses were unevenly distributed.

A Changing Standard of Pain Care

The introduction coincided with the spread of Pain as the fifth vital sign, an approach that placed pain alongside blood pressure, heart rate, respiratory rate, and temperature. Hospitals and doctors were also facing a stronger consumer-oriented model of health care: patients rated their experiences in formal surveys, and institutions competed for high scores. Because reimbursements could be affected by those assessments, the system gave clinicians an incentive to treat pain liberally. In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for pain assessment and treatment, further embedding the change in hospital practice.

The shift answered a genuine concern. A 2000 New York Times account described an older nursing-home resident with severe osteoporosis and pulmonary disease who received only Tylenol for her pain. The case reflected a widespread view among health-care experts that pain had long been undertreated, in part because workers feared that adequate relief would cause addiction. OxyContin arrived amid this concern, offering a prescription product at a moment when clinicians were being urged to recognize and respond to pain more consistently.

Purdue Pharma's Safety Claims and Promotion

Purdue Pharma promoted OxyContin for chronic pain beyond cancer, presenting it as suitable for patients with conditions ranging from moderate back injuries and wisdom-tooth surgery to bronchitis and temporomandibular joint disorder. Its medical representative, David Haddox, told clinicians that addiction risk was less than 1 percent when the medicine was taken as prescribed. In a 1996 training session, the company characterized doctor-caused addiction as exceptionally rare. Those claims helped frame prescribing as a responsible and compassionate response to pain, while Purdue's sales representatives carried the message to doctors and dentists across all fifty states.

The campaign extended beyond drug promotion into the institutional environment where pain standards were being implemented. In a 2000 budget plan, the company saw an opportunity to present itself as a leader in helping hospitals meet the Joint Commission's requirements through pain-assessment and management materials. It budgeted $300,000 for OxyContin-branded scroll pens, $225,000 for resource binders, and $290,000 for wall charts and clipboards bearing the Pain as the fifth vital sign message. These items made the brand part of the ordinary visual and administrative landscape of care, linking Purdue's commercial presence to a professional effort that had independent reasons for addressing undertreated pain.

Unequal Exposure and Enforcement

The later opioid crisis revealed that exposure to prescription painkillers and punishment for drug activity did not fall evenly across racial groups. Research cited in the book found that, by 2014, doctors prescribed painkillers to people of color at substantially lower rates than to white patients, amid clinicians' distrust that patients of color would misuse opioids. The account describes this disparity as a possible protective effect against one form of opioid exposure: while overdose deaths among young white people had risen to three times their 2002 rate, the death rate among people of color was relatively unchanged.

That difference in prescribing existed alongside a stark contrast in criminal enforcement. The book notes that three-quarters of federal drug offenders were Black or Hispanic and that people of color made up 57 percent of people imprisoned for drug offenses in state systems. Its account warns against treating the slogan that arrests cannot solve the opioid problem as a universal principle: the rhetoric was often applied to mostly white opioid users, while people such as Ronnie Jones and other Black and brown defendants continued to face imprisonment for drug distribution. The launch did not by itself explain these disparities, but the epidemic's history placed medical decisions and drug policing within the same unequal landscape.

Crisis Responses and the Treatment Gap

By 2015, Roanoke's response to rising heroin use included the Hope Initiative, a local version of the Police Assisted Addiction and Recovery Initiative. Roanoke Police Chief Chris Perkins hoped trained volunteers, or angels, could guide people toward treatment and support them through a difficult recovery process. The program was based at the Bradley Free Clinic. Its coordinator, Janine Underwood, joined not only as the clinic's executive director but also as a bereaved mother: her son Bobby Baylis had died after using fentanyl-laced heroin. His history included addiction that began after OxyContin was prescribed following surgery, a path that brought the broader crisis into a local family's experience.

The initiative's early results exposed how much separated a request for help from treatment itself. Twenty-two people came to the program in its first month, but none entered residential care, and only a handful obtained outpatient medication-assisted treatment. Elsewhere in the local system, efforts to create a smooth transfer from emergency departments to medication-assisted treatment and counseling encountered legal, financial, and administrative barriers, including too few providers and detoxification and treatment beds. Janine also helped coordinate an out-of-state residential placement for a patient leaving detox, persuading the facility to keep him an extra day while his family arranged the transfer. These later responses do not establish that the launch alone produced the crisis; they show the enduring difficulty of translating recognition of opioid addiction into timely, sustained care.